Prexasertib
As of the edition of 20 October 2026, Prexasertib is a small molecule: in active development; acts on CHEK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 20, 2 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Lungs and airways; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHEK1 | Serine/threonine-protein kinase Chk1 | O14757 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 12 | 11 | 0 | 1 |
| Phase 2 | 8 | 5 | 2 | 1 |
| All trials | 20 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2010 to now |
| Acrivon Therapeutics | Lead sponsor of trials | 2022 to now |